Novant announced the creation of the institute in June. The institute was launched with the mission of using AI and other advanced technology to generate data and insights for more personalized and accurate disease prediction, diagnosis and treatment, through collaborations with Novant’s physician partners, technology companies, research groups, universities and other healthcare organizations.
As the institute’s first partner, Jvion will apply its AI-enabled analytics to clinical and socioeconomic data from Novant and other government and private sources. Together, the organizations hope to develop a solution to recommend personalized treatments for congestive heart failure patients, with an ultimate goal of reducing readmissions for those patients.
“Partnering with innovators in analytics such as Jvion allows us to anticipate risk factors and effectively intervene through personalized treatment plans for our patients, saving time and money,” said Eric Eskioglu, MD, Novant’s executive vice president and chief medical officer, and co-leader of the new institute. “The implementation of this technology will transform the way we deliver care for our patients with CHF across the Carolinas and Virginia, thereby improving their quality of life and preventing unnecessary readmissions.”
Editor’s note: This article was updated on Sept. 18 at 2:35 p.m. to clarify details of the partnership.
More articles on innovation:
HHS expands health security-focused network of innovation accelerators
Viewpoint: Implementing the ’10 laws of trust’ will create a culture of innovation
Nearly 60% of Fortune 1000 companies will increase innovation investment in 2020, survey finds
